SAN FRANCISCO, April 13, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results